**
A groundbreaking vaccine administered during pregnancy has been shown to significantly decrease hospital admissions for newborns suffering from respiratory syncytial virus (RSV) by over 80%, according to UK health officials. The vaccine, offered to expectant mothers starting from 28 weeks of gestation, provides vital protection against severe respiratory infections that can affect infants in their first months of life.
Understanding RSV and Its Impact on Newborns
Respiratory syncytial virus is a leading cause of serious respiratory illness in young children, with more than 20,000 infants requiring hospital treatment in the UK each year. The virus can lead to severe respiratory distress, manifesting as wheezing, difficulty in breathing, and feeding challenges. Tragically, a number of infants lose their lives to infections caused by RSV annually.
Dr Conall Watson, the national programme lead for RSV at the UK Health Security Agency (UKHSA), emphasised the distressing nature of RSV infections. “When babies exhibit respiratory distress, it is incredibly alarming for parents,” he noted, highlighting the urgency of the situation.
The Introduction of the Vaccine
Since its rollout in 2024, the RSV vaccine has been demonstrated to enhance the immune response in pregnant women, allowing them to transfer antibodies to their babies via the placenta. This transfer of immunity means that newborns are protected from the moment of birth, a crucial time when they are particularly susceptible to infections.
Recent research analysing the effectiveness of the vaccine revealed an impressive efficacy rate of nearly 85% when administered at least four weeks prior to delivery. The findings suggest that even a two-week interval between vaccination and birth can still confer some level of protection, underscoring the importance of timely immunisation. Dr Watson urged expectant mothers to receive the vaccine during their third trimester, stating, “If you have a longer interval between vaccination and delivery, you will receive even better protection.”
Study Findings and Hospitalisation Rates
The new study tracked nearly 300,000 births in England between September 2024 and March 2025, which represents approximately 90% of all births during that period. The data revealed that more than 4,500 infants were admitted to hospital, with the vast majority of these cases involving babies whose mothers had not received the RSV vaccine.
One poignant case highlighted the potential consequences of RSV infection. Laine Lewis’s son, Malachi, now 12 years old, faced severe health challenges after contracting the virus as an infant. He was diagnosed with RSV after developing a cold and required oxygen support. Tragically, he later suffered brain damage. Lewis has since advocated for the vaccine, stating, “I would encourage people to take the vaccine for RSV because it will help their child.”
Current Vaccination Rates
Encouragingly, recent statistics indicate that approximately 64% of pregnant women in England are receiving the RSV vaccine. However, the uptake falls to 53% in London, illustrating regional disparities in vaccination coverage. Alongside the RSV vaccine, pregnant women are also advised to receive vaccinations for flu and whooping cough, which further underscores the importance of maternal immunisation in safeguarding newborn health.
In addition to pregnant women, adults aged 75 and older, as well as those residing in care homes, are also being offered the RSV vaccine as part of the UK’s broader public health strategy.
Why it Matters
The introduction of the RSV vaccine represents a significant advancement in public health, particularly for vulnerable populations such as newborns. By drastically reducing hospital admissions and associated health risks, this initiative not only protects individual infants but also alleviates pressure on healthcare systems during peak respiratory illness seasons. As maternal vaccination coverage improves, it is expected that the overall health outcomes for infants will continue to enhance, highlighting the critical role of preventive measures in public health strategy.
